European Society of Cardiology: Beta-blockers Reduced Cardiovascular Events in Selected Heart Attack Patients Without Heart Failure in BETAMI-DANBLOCK Trials
August 30, 2025
August 30, 2025
SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release:
* * *
Beta-blockers reduced cardiovascular events in selected heart attack patients without heart failure in the BETAMI-DANBLOCK trials
* While beta-blockers are strongly recommended for patients with myocardial infarction (MI) and reduced left ventricular ejection fraction (LVEF), their role in patients with preserved or mildly reduced LVEF (40%) is l . . .
* * *
Beta-blockers reduced cardiovascular events in selected heart attack patients without heart failure in the BETAMI-DANBLOCK trials
* While beta-blockers are strongly recommended for patients with myocardial infarction (MI) and reduced left ventricular ejection fraction (LVEF), their role in patients with preserved or mildly reduced LVEF (40%) is l . . .